Home > Reports > Europe Diabetes Devices Market Demand, Share, Forecast to 2030

Europe Diabetes Devices Market

Europe Diabetes Devices Market Size is Expected to Reach USD 14965 Million With a CAGR of 6.5% by 2030

Published On : 14 Nov, 2022
Updated On : 20 Nov, 2022
Table of Content Download Sample

Market Snapshot

Base Year:
2021
Study Period:
2020-2030
CAGR:
6.35 %

Diabetes occurs when the pancreas is unable to create insulin from the blood. Increased blood sugar levels induce untreated diabetes. Diabetes drugs are used to treat diabetes in specific. The purpose of diabetic treatment is to raise blood glucose levels. Diabetes care gadgets are used to monitor blood glucose levels in diabetics. A continuous glucose monitor (CGM) is a medical device that tracks and monitors the blood glucose levels of diabetes patients throughout the day. This wearable device will benefit those with diabetes since it can help them manage their glucose levels. Diabetic monitoring equipment includes ketone metres, blood glucose meters, continuous glucose metres, insulin pumps, smart insulin pens, and diabetes management software. Glucose monitoring devices help patients maintain and control their glucose levels, improving their health.

During the projected period, the Europe Diabetes Devices Market is expected to increase at a CAGR of 6.35 %, reaching a total value of 14965 million USD in 2030. Diabetic patients are increasing in Europe because of the rising prevalence of diabetes, the ageing population, bad eating habits, and rising levels of physical inactivity in the region.

Get more information on this report Download Sample Report

Market Dynamics

Key Market Drivers

  • Diabetes Care is Getting More Attention: Due to the increasing number of European governments and charitable activities aimed at raising diabetes awareness, the use of diabetic devices is expected to rise. Similarly, the WHO and the IDF work together to prevent and control diabetes while also guaranteeing a high quality of life for people all over the world. The WHO Diabetes Program, for example, strives to prevent type 2 diabetes, reduce complications, and improve the quality of life of diabetes patients. NGOs and governments are defining norms and standards, boosting diabetes prevention awareness, and supporting monitoring to improve diabetes prevention and control. As a result, the growing number of diabetes awareness campaigns is anticipated to lead to an increase in diabetes diagnosis and, as a result, the use of diabetic devices.
  • An increase in the number of people using insulin: The high market share is due to the increase in the number of insulin users among the diabetes population. The prevalence of diabetes is growing among all ages in Europe, which may be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles of people. As a result, more and more people are advised to take insulin by doctors and hence the demand is expected to grow because of this.

Key Market Restraints

  • Insulin delivery devices and their negative impact: Pump or site failure can cause diabetic ketoacidosis (DKA) and Skin infection or allergic response are the negative impacts that have been reported in Europe which is a cause of concern and can serve as a restraint for the growth of the market.
  • Errors in the result: Blood glucose metres can occasionally cause issues. Falsely high or low findings, as well as inaccurate calibration, are examples of performance issues. The metre or the test strips could be to blame for the mistakes. Failure to turn on or switching to the wrong units are examples of problems caused by faulty manufacturing. Error in the results can be due to several reasons and this might create trust issues in the minds of customers and can serve as a restraint.

Key Market Opportunities

  • Europe’s Diabetic Population Is Growing: In 2020, diabetes and its complications are predicted to cause roughly 4.5 million deaths in people aged 20 to 79. This means that one person dies every eight minutes. Diabetes accounts for 11.95% of all deaths among adults in this age group. Diabetes and high glucose levels have been associated to an increased risk of complications, respiratory failure, and death in hospitalized Coronavirus patients. Diabetes has been connected to a variety of health issues. People with diabetes have a 300% higher risk of being hospitalized than people without diabetes, resulting in higher healthcare costs. Children and teenagers are more prone to develop diabetes early due to their young age and longer diabetes duration, reducing their quality of life, shortening their life expectancy, and raising healthcare costs. As a result, diabetes is expected to grow more prevalent in the future in the European region. There is also concern that, as a result of modern lifestyle and technology advancements, diabetes will occur at a higher rate in kids and young adults, resulting in increased use of diabetes care devices.

Segment Overview

The Europe diabetes devices market segment has been categorized by type, distribution channel, and application.

According to type, the diabetes devices market is divided into blood glucose monitoring devices and insulin administration devices. The insulin delivery devices sector is likely to lead the market, with a projected value of USD 30,412.19 million by 2030, representing a 7.62% CAGR over the forecast period.

The expanding number of rules and approvals for technological developments in insulin delivery devices such as insulin pens, insulin pumps, jet injectors, and other devices are some of the key driving factors for demand for insulin delivery devices. The growing acceptability of insulin patches and smart insulin pumps for diabetes self-management is one of the factors boosting demand for insulin delivery devices.

Based on the distribution channel, the diabetic devices market has been divided into hospitals, retail pharmacies, diabetes clinics/centres, internet pharmacies, and others. The retail pharmacies sector is estimated to lead the market, with revenues of USD 11,491.59 million by 2030, representing a CAGR of 6.92 percent over the forecast period. Some of the reasons projected to promote the growth of the retail sales segment over the projection period include the rising penetration of private-label products in retail stores at lower prices.

Based on application, the diabetic devices market has been divided into hospitals, home care, and diagnostic centres. The hospital's category is likely to lead the market, with revenues of USD 19,845.68 million expected by 2030, representing a CAGR of 6.42 percent during the forecast period. Diabetic people are increasingly being admitted to hospitals.

Type 1 diabetes patients had longer hospital stays, a higher death rate, and more complications than type 2 diabetes patients. Type 1 diabetes patients are administered insulin to prevent ketoacidosis, although they have a higher rate of hyperglycemia. As a result, an increase in the number of type 1 diabetes patients in hospitals, as well as an increase in the demand for continuous blood glucose monitoring, are two factors pushing up the demand.

Regional Overview

Europe Diabetes Devices Market Countrywise Analysis

Regional Growth Insights Request Sample Pages

The Europe Diabetes Devices Market is predicted to be the second largest. Factors such as an increase in the number of diabetic patients and improved awareness about diabetes treatment and control are expected to contribute to market growth over the forecast period. Due to the increased prevalence of diabetes and obesity in the country, Germany dominated the market during the historical era, and this trend is likely to continue during the forecast decade. Diabetes prevalence varies greatly across Europe, with figures ranging from 2.8 percent in Albania to 9.8 percent in Portugal. Diabetes is one of the primary causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation in high-income countries.

In 2021, Germany had the biggest market share of 28.2 percent in the European diabetes care devices market, followed by Russia and France. Test strips have the largest market share in Germany, accounting for more than half of the total market, followed by insulin pens. The German market is large and predicted to expand rapidly throughout the projection period. The diabetes care devices market in Germany will grow in the projected period as the country's diabetes population grows. Germany's diabetes population is currently at 8 million people.

Due to the increased incidence rate of diabetes and obesity in this country, the UK diabetic devices market is predicted to grow significantly in the European market, with roughly 3.8 million people suffering from diabetes. Furthermore, the rise of this region is fuelled by bad eating habits and diets, increased levels of physical activity, and greater access to blood glucose monitoring devices.

France is a significant European country. Diabetes is on the rise in our country, with approximately 3.2 million people diagnosed. The number of people with diabetes is predicted to rise among all ages as a result of rising obesity rates, increased awareness, and increased healthcare spending, which is driving the market in this country.

Countries such as Russia and Italy are known for having large populations with Type 1 diabetes, especially among young individuals.

Major Players

Some major players in the Europe Region (having significant market share) are listed below:

  • Dexcom
  • Medtronic
  • Omnipod
  • Novo Nordisk
  • Hoffmann-La Roche AG
  • Sanofi
  • Rossmax
  • Eli Lilly

Recent Developments

  • Medtronic received CE certification for their InPen smart insulin pen and Guardian 4 sensor for enhanced diabetes control in May 2021.
  • NHS England stated in June 2021 that hybrid closed-loop systems, commonly known as an artificial pancreas, will be available to adults and children on the NHS in England.

Europe Diabetes Devices Market: Segmentation

By Type

  • Blood Glucose Monitoring Devices
  • Insulin Delivery Devices

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Diabetes Clinics/Centers
  • Online Pharmacies
  • Others

By Application

  • Hospitals
  • Homecare
  • Diagnostics Centers

By Country

  • United Kingdom
  • France
  • Germany
  • Italy
  • Russia
  • Spain
  • Rest of Europe
Price Starts From
$3250

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers